No Data
Lee's Pharma Unit's Therapeutic Biological Products Gets NMPA's Go-Ahead for Clinical Trials
Lee's Pharm Advances With New Drug Application
Lee's Pharm (00950.HK): Recombinant Anfibopeptide Injection may receive a notice of acceptance for clinical trial drug application.
On October 14, Gleway announced that on September 25, 2024, the China National Medical Products Administration ("National Medical Products Administration") accepted the application for the clinical trial of the recombination anfibopeptide injection, with acceptance numbers CXSL2400638 and CXSL2400639. This is the first clinical trial registration application for this product, with submitted clinical plans including Phase I (single and multiple doses) and Phase II clinical plans. The recombination anfibopeptide injection is a type of therapeutic biological product discovered and owned by the group's wholly-owned subsidiary, Zhaok Pharmaceutical (Hefei) Co., Ltd.
Lee's Pharm (00950): The clinical trial application for the recombination of Anfibopeptide injection has been accepted.
lee's pharm (00950) announced that on September 25, 2024, the China National Medical Products Administration received...
Express News | Lee's Pharmaceutical Holdings Ltd - on 25 Sept, Nmpa Accepted Application for Clinical Trial of Recombinant Anfibatide Injection
LEE'S PHARM: Interm Report 2024
Lee's Pharmaceutical Holdings Limited (HKG:950) Surges 29% Yet Its Low P/S Is No Reason For ExcitementNo Data
No Data
